The Reciprocal Relationship Between Inflammation and Coagulation

Topics in Companion Animal Medicine

Volumn 27, Issue 2, 2012, Pages 46-52

  O'Brien, Mauria ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Cytokines; Endothelium; Hemostasis; Immune; Sepsis; Toll like receptor

Indexed keywords

ANTITHROMBIN; CYTOKINE; PLASMIN; PROTEINASE ACTIVATED RECEPTOR; THROMBIN;

ANIMAL; ANIMAL DISEASE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CAT; DOG; DOWN REGULATION; FIBRINOLYSIS; IMMUNOLOGY; INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; CATS; CYTOKINES; DOGS; DOWN-REGULATION; FIBRINOLYSIN; FIBRINOLYSIS; INFLAMMATION; RECEPTOR CROSS-TALK; RECEPTORS, PROTEINASE-ACTIVATED; THROMBIN;

EID: 84866989789     PISSN: 19389736     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.tcam.2012.06.003     Document Type: Review

References (110)

1. Hoffmann J.A., Reichhart J.M. Drosophila innate immunity: an evolutionary perspective. Nat Immunol 2002, 3:121-126.
2. Opal S.M. The nexus between systemic inflammation and disordered coagulation in sepsis. J Endotoxin Res 2004, 10:125-129.
3. Lipinski S., Bremer L., Lammers T., Thieme F., Schreiber S., Rosenstiel P. Coagulation and inflammation. Molecular insights and diagnostic implications. Hamostaseologie 2011, 31:94-102. 104.
4. Bone R.C., Grodzin C.J., Balk R.A. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997, 112:235-243.
5. van der Poll T., Opal S.M. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008, 8:32-43.
6. Veldman A., Fischer D. The search for a unified theory of coagulation and inflammation. Cell Mol Life Sci 2004, 61:2744-2749.
7. Opal S.M. Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin Respir Crit Care Med 2011, 32:569-580.
8. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
9. Otto C.M. Sepsis in veterinary patients: what do we know and where can we go?. J Vet Emerg Crit Care 2007, 17:329-332.
10. Levi M., Opal S.M. Coagulation abnormalities in critically ill patients. Crit Care 2006, 10:222.
11. Strauss R., Wehler M., Mehler K., Kreutzer D., Koebnick C., Hahn E.G. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002, 30:1765-1771.
12. Parker R.I. Thrombocytopenia and intensive care unit outcome: a sticky issue. Crit Care Med 2002, 30:1917-1918.
13. Chong D.L., Sriskandan S. Pro-inflammatory mechanisms in sepsis. Contrib Microbiol 2011, 17:86-107.
14. Müller S., Ronfani L., Bianchi M.E. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 2004, 255:332-343.
15. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
16. Thoma-Uszynski S., Stenger S., Takeuchi O., et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001, 291:1544-1547.
17. Kumar H., Kawai T., Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011, 30:16-34.
18. Doyle S.L., O'Neill L.A. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006, 72:1102-1113.
19. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
20. Tsujimoto H., Ono S., Majima T., et al. Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock 2005, 23:39-44.
21. Levi M., ten Cate H., van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002, 30:S220-S224.
22. Kaneider N.C., Leger A.J., Agarwal A., et al."Role reversal" for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007, 8:1303-1312.
23. Slifka M.K., Whitton J.L. Clinical implications of dysregulated cytokine production. J Mol Med (Berl) 2000, 78:74-80.
24. Dinarello C.A. Proinflammatory cytokines. Chest 2000, 118:503-508.
25. Kirchhofer D., Tschopp T.B., Hadváry P., Baumgartner H.R. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest 1994, 93:2073-2083.
26. Morrissey J.H. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001, 86:66-74.
27. Nemerson Y. Tissue factor and hemostasis. Blood 1988, 71:1-8.
28. Morrissey J.H., Macik B.G., Neuenschwander P.F., Comp P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993, 81:734-744.
29. Monroe D.M., Roberts H.R., Hoffman M. Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol 1994, 88:364-371.
30. Colucci M., Balconi G., Lorenzet R., et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983, 71:1893-1896.
31. Semeraro N., Biondi A., Lorenzet R., Locati D., Mantovani A., Donati M.B. Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites. Immunology 1983, 50:529-535.
32. Rothberger H., Zimmerman T.S., Spiegelberg H.L., Vaughan J.H. Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest 1977, 59:549-557.
33. Conkling P.R., Greenberg C.S., Weinberg J.B. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988, 72:128-133.
34. Bevilacqua M.P., Gimbrone M.A. Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost 1987, 13:425-433.
35. Bevilacqua M.P., Pober J.S., Majeau G.R., Cotran R.S., Gimbrone M.A. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984, 160:618-623.
36. Niemetz J., Marcus A.J. The stimulatory effect of platelets and platelet membranes on the procoagulant activity of leukocytes. J Clin Invest 1974, 54:1437-1443.
37. Pinder P.B., Hunt J.A., Zacharski L.R. In vitro stimulation of monocyte tissue factor activity by autologous platelets. Am J Hematol 1985, 19:317-325.
38. Szotowski B., Antoniak S., Poller W., Schultheiss H.P., Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005, 96:1233-1239.
39. Zillmann A., Luther T., Müller I., et al. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001, 281:603-609.
40. Müller I., Klocke A., Alex M., et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003, 17:476-478.
41. Egorina E.M., Sovershaev M.A., Olsen J.O., Østerud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood 2008, 111:1208-1216.
42. Hsu-Lin S., Berman C.L., Furie B.C., August D., Furie B. A platelet membrane protein expressed during platelet activation and secretion. Studies using a monoclonal antibody specific for thrombin-activated platelets. J Biol Chem 1984, 259:9121-9126.
43. Larsen E., Celi A., Gilbert G.E., et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989, 59:305-312.
44. Stenberg P.E., McEver R.P., Shuman M.A., Jacques Y.V., Bainton D.F. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985, 101:880-886.
45. Bonfanti R., Furie B.C., Furie B., Wagner D.D. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989, 73:1109-1112.
46. McEver R.P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001, 86:746-756.
47. Frenette P.S., Denis C.V., Weiss L., et al. P-selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000, 191:1413-1422.
48. Koike J., Nagata K., Kudo S., Tsuji T., Irimura T. Density-dependent induction of TNF-alpha release from human monocytes by immobilized P-selectin. FEBS Lett 2000, 477:84-88.
49. Tsuji T., Nagata K., Koike J., Todoroki N., Irimura T. Induction of superoxide anion production from monocytes and neutrophils by activated platelets through the P-selectin-sialyl Lewis X interaction. J Leukoc Biol 1994, 56:583-587.
50. Celi A., Pellegrini G., Lorenzet R., et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 1994, 91:8767-8771.
51. del Conde I., Nabi F., Tonda R., Thiagarajan P., López J.A., Kleiman N.S. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arterioscler Thromb Vasc Biol 2005, 25:1065-1070.
52. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 2005, 131:417-430.
53. Mollen K.P., Anand R.J., Tsung A., Prince J.M., Levy R.M., Billiar T.R. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006, 26:430-437.
54. Chow J.C., Young D.W., Golenbock D.T., Christ W.J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999, 274:10689-10692.
55. Clark S.R., Ma A.C., Tavener S.A., et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007, 13:463-469.
56. Ma A.C., Kubes P. Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. J Thromb Haemost 2008, 6:415-420.
57. Cinel I., Opal S.M. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009, 37:291-304.
58. Kaplanski G., Marin V., Fabrigoule M., et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106). Blood 1998, 92:1259-1267.
59. Ma L., Dorling A. The roles of thrombin and protease-activated receptors in inflammation. Semin Immunopathol 2012, 34:63-72.
60. Lorant D.E., Patel K.D., McIntyre T.M., McEver R.P., Prescott S.M., Zimmerman G.A. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biol 1991, 115:223-234.
61. Johnson K., Choi Y., DeGroot E., Samuels I., Creasey A., Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998, 160:5130-5135.
62. Anas A.A., Wiersinga W.J., de Vos A.F., van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010, 68:147-152.
63. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999, 103:879-887.
64. Ossovskaya V.S., Bunnett N.W. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004, 84:579-621.
65. Nystedt S., Ramakrishnan V., Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J Biol Chem 1996, 271:14910-14915.
66. Camerer E., Rottingen J.A., Gjernes E., et al. Coagulation factors IA, VI and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999, 274:32225-32233.
67. Kumar P., Shen Q., Pivetti C.D., Lee E.S., Wu M.H., Yuan S.Y. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med 2009, 11:e19.
68. Bae J.S., Yang L., Manithody C., Rezaie A.R. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007, 110:3909-3916.
69. Anrather D., Millan M.T., Palmetshofer A., et al. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF. J Immunol 1997, 159:5620-5628.
70. Grandel U., Grimminger F. Endothelial responses to bacterial toxins in sepsis. Crit Rev Immunol 2003, 23:267-299.
71. Dauphinee S.M., Karsan A. Lipopolysaccharide signaling in endothelial cells. Lab Invest 2006, 86:9-22.
72. van Hinsbergh V.W. Endothelium-role in regulation of coagulation and inflammation. Semin Immunopathol 2012, 34:93-106.
73. Bauer K.A., Rosenberg R.D. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol 1991, 28:10-18.
74. Nevière R., Tournoys A., Mordon S., et al. Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats. Shock 2001, 15:220-225.
75. Yamashiro K., Kiryu J., Tsujikawa A., et al. Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2001, 42:1553-1560.
76. Okajima K., Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost 1998, 24:27-32.
77. Oelschläger C., Römisch J., Staubitz A., et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002, 99:4015-4020.
78. Souter P.J., Thomas S., Hubbard A.R., Poole S., Römisch J., Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001, 29:134-139.
79. Kaneider N.C., Reinisch C.M., Dunzendorfer S., Römisch J., Wiedermann C.J., Wiederman C.J. Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 2002, 115:227-236.
80. Blauhut B., Kramar H., Vinazzer H., Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 1985, 39:81-89.
81. Warren B.L., Eid A., Singer P., et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878.
82. Kobayashi M., Shimada K., Ozawa T. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990, 144:383-390.
83. Minnema M.C., Chang A.C., Jansen P.M., et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000, 95:1117-1123.
84. Conway E.M. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012, 34:107-125.
85. Van de Wouwer M., Plaisance S., De Vriese A., et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006, 4:1813-1824.
86. Shi C.S., Shi G.Y., Hsiao S.M., et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008, 112:3661-3670.
87. Abeyama K., Stern D.M., Ito Y., et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005, 115:1267-1274.
88. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
89. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
90. Saito H., Maruyama I., Shimazaki S., et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007, 5:31-41.
91. Cheng T., Liu D., Griffin J.H., et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003, 9:338-342.
92. Feistritzer C., Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005, 105:3178-3184.
93. Griffin J.H., Fernández J.A., Gale A.J., Mosnier L.O. Activated protein C. J Thromb Haemost 2007, 1(5 Suppl):73-80.
94. Nick J.A., Coldren C.D., Geraci M.W., et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004, 104:3878-3885.
95. Joyce D.E., Nelson D.R., Grinnell B.W. Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit Care Med 2004, 32:S280-S286.
96. Yuksel M., Okajima K., Uchiba M., Horiuchi S., Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002, 88:267-273.
97. Chaput C., Zychlinsky A. Sepsis: the dark side of histones. Nat Med 2009, 15:1245-1246.
98. Song D., Ye X., Xu H., Liu S.F. Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood 2009, 114:2521-2529.
99. Dellinger R.P., Carlet J.M., Masur H., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873.
100. Wiedermann C.J. Bioethics, the Surviving Sepsis Campaign, and the industry. Wien Klin Wochenschr 2005, 117:442-444.
101. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
102. Wiedermann C.J. When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated). Intensive Care Med 2006, 32:604.
103. FDA Drug Safety Communication: Voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit Accessed 21 June 2012. http://www.fda.gov/Drugs/DrugSafety/ucm277114.htm.
104. Feistritzer C., Schuepbach R.A., Mosnier L.O., et al. Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem 2006, 281:20077-20084.
105. de Jonge E., Dekkers P.E., Creasey A.A., et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000, 95:1124-1129.
106. Tang H., Ivanciu L., Popescu N., et al. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol 2007, 171:1066-1077.
107. Eling M., Stephens A.C., Oragui E.E., Rivers R.P., Levin M. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease. Thromb Haemost 2001, 85:240-244.
108. Laterre P.F., Opal S.M., Abraham E., et al. A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care 2009, 13:R36.
109. Abraham E., Reinhart K., Svoboda P., et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001, 29:2081-2089.
110. Abraham E., Reinhart K., Opal S., et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290:238-247.